Hemoglobin Targets for Chronic Kidney Disease Patients with Anemia: A Systematic Review and Meta-analysis

PLoS ONE

Volumn 7, Issue 8, 2012, Pages

  Jing, Zhou ^a   Wei jie, Yuan ^a   Nan, Zhu ^a   Yi, Zhou ^a   Ling, Wang ^a  

^a SHANGHAI JIAO TONG UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ERYTHROPOIETIN; HEMOGLOBIN; PLACEBO;

ANEMIA; ARTICLE; CHRONIC KIDNEY DISEASE; COCHRANE LIBRARY; DRUG EFFICACY; DRUG SAFETY; DRUG TARGETING; EMBASE; HEART INFARCTION; HEMOGLOBIN BLOOD LEVEL; HOSPITALIZATION; HUMAN; HYPERTENSION; MEDLINE; MORTALITY; OUTCOME ASSESSMENT; RANDOMIZED CONTROLLED TRIAL (TOPIC); RENAL REPLACEMENT THERAPY; RISK ASSESSMENT; STROKE; SYSTEMATIC REVIEW;

ANEMIA; CLINICAL TRIALS AS TOPIC; HEMOGLOBINS; HUMANS; RENAL INSUFFICIENCY, CHRONIC;

EID: 84865608453     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0043655     Document Type: Article

References (41)

1. Astor BC, Muntner P, Levin A, Eustace JA, Coresh J, (2002) Association of kidney function with anemia: the Third National Health and Nutrition Examination Survey (1988-1994). Arch Intern Med 162: 1401-1408.
2. Regidor D, Mcclellan WM, Kewalramani R, Sharma A, Bradbury BD, (2011) Changes in erythropoiesis-stimulating agent (ESA) dosing and haemoglobin levels in US non-dialysis chronic kidney disease patients between 2005 and 2009. Nephrol Dial Transplant 26: 1583-1591.
3. Watson AJ, (1989) Adverse effects of therapy for the correction of anemia in hemodialysis patients. Semin Nephrol 9: 30-34.
4. Singh AK, Szczech L, Tang KL, Barnhart H, Sapp S, et al. (2006) Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med 355: 2085-2098.
5. Drueke TB, Locatelli F, Clyne N, Eckardt KU, Macdougall IC, et al. (2006) Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med 355: 2071-2084.
6. National Kidney Foundation, KDOQI (2001) IV. NKF-K/DOQI Clinical Practice Guidelines for Anemia of Chronic Kidney Disease: update 2000. Am J Kidney Dis 37: S182-238.
7. KDOQI (2006) KDOQI Clinical Practice Guidelines and Clinical Practice Recommendations for Anemia in Chronic Kidney Disease. Am J Kidney Dis 47: S11-145.
8. National Kidney Foundation (2006) II. Clinical practice guidelines and clinical practice recommendations for anemia in chronic kidney disease in adults. Am J Kidney Dis 47: S16-85.
9. KDOQI (2007) KDOQI Clinical Practice Guideline and Clinical Practice Recommendations for anemia in chronic kidney disease: 2007 update of hemoglobin target. Am J Kidney Dis 50: 471-530.
10. Mactier R, Davies S, Dudley C, Harden P, Jones C, et al. (2011) Summary of the 5th edition of the Renal Association Clinical Practice Guidelines (2009-2012). Nephron Clin Pract 118 Suppl 1: c27-c70.
11. Higgins JPT, Green S, editors. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration. Available from www.cochrane-handbook.org.
12. Higgins JP, Thompson SG, Deeks JJ, Altman DG, (2003) Measuring inconsistency in meta-analyses. BMJ 327: 557-60.
13. DerSimonian R, Laird N, (1986) Meta-analysis in clinical trials. Control Clin Trials 7: 177-188.
14. Akizawa T, Gejyo F, Nishi S, Lino Y, Watanabe Y, et al. (2011) Positive outcomes of high hemoglobin target in patients with chronic kidney disease not on dialysis: a randomized controlled study. Ther Apher Dial 15: 431-440.
15. Villar E, Lievre M, Kessler M, Lernaitre V, Alamartine E, et al. (2011) Anemia normalization in patients with type 2 diabetes and chronic kidney disease: results of the NEPHRODIAB2 randomized trial. J Diabetes Complications 25: 237-243.
16. Cianciaruso B, Ravani P, Barrett BJ, Levin A, (2008) ITA-EPO-7 investigators (2008) Italian randomized trial of hemoglobin maintenance to prevent or delay left ventricular hypertrophy in chronic kidney disease. J Nephrol 21: 861-870.
17. Ritz E, Laville M, Bilous RW, ODonoghue D, Scherhag A, et al. (2007) Target level for hemoglobin correction in patients with diabetes and CKD: primary results of the Anemia Correction in Diabetes (ACORD) Study. Am J Kidney Dis 49: 194-207.
18. Parfrey PS, Foley RN, Wittreich BH, Sullivan DJ, Zagari MJ, et al. (2005) Double-blind comparison of full and partial anemia correction in incident hemodialysis patients without symptomatic heart disease. J Am Soc Nephrol 16: 2180-2189.
19. Levin A, Djurdjev O, Thompson C, Barrett B, Ethier J, et al. (2005) Canadian randomized trial of hemoglobin maintenance to prevent or delay left ventricular mass growth in patients with CKD. Am J Kidney Dis 46: 799-811.
20. Roger SD, Mcmahon LP, Clarkson A, Disney A, Harris D, et al. (2004) Effects of early and late intervention with epoetin alpha on left ventricular mass among patients with chronic kidney disease (stage 3 or 4): results of a randomized clinical trial. J Am Soc Nephrol 15: 148-156.
21. Gouva C, Nikolopoulos P, Ioannidis JP, Siamopoulos KC, (2004) Treating anemia early in renal failure patients slows the decline of renal function: a randomized controlled trial. Kidney Int 66: 753-760.
22. Furuland H, Linde T, Ahlmen J, Christensson A, Strombom U, et al. (2003) A randomized controlled trial of haemoglobin normalization with epoetin alfa in pre-dialysis and dialysis patients. Nephrol Dial Transplant 18: 353-361.
23. Foley RN, Parfrey PS, Morgan J, Barre PE, Campbell P, et al. (2000) Effect of hemoglobin levels in hemodialysis patients with asymptomatic cardiomyopathy. Kidney Int 58: 1325-1335.
24. Conlon PJ, Kovalik E, Schumm D, Minda S, Schwab SJ, (2000) Normalization of hematocrit in hemodialysis patients with cardiac disease does not increase blood pressure. Ren Fail 22: 435-444.
25. Berns JS, Rudnick MR, Cohen RM, Bower JD, Wood BC, (1999) Effects of normal hematocrit on ambulatory blood pressure in epoetin-treated hemodialysis patients with cardiac disease. Kidney Int 56: 253-260.
26. Besarab A, Bolton WK, Browne JK, Egrie JC, Nissenson AR, et al. (1998) The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N Engl J Med 339: 584-590.
27. Canadian Erythropoietin Study Group (1990) Association between recombinant human erythropoietin and quality of life and exercise capacity of patients receiving haemodialysis. Canadian Erythropoietin Study Group. BMJ 300: 573-578.
28. Patel M, Thimons DG, Winston JL, Langholff W, McGowan T, (2012) An Open-Label, Randomized, Multicenter, Controlled Study of Epoetin Alfa for the Treatment of Anemia of Chronic Kidney Disease in the Long Term Care Setting. JAMDA 13: 244-248.
29. Pfeffer MA, Burdmann EA, Chen CY, Cooper ME, de Zeeuw D, et al. (2009) A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. N Engl J Med 361: 2019-2032.
30. Pappas KD, Gouva CD, Katopodis KP, Nikolopoulos PM, Korantzopoulos PG, et al. (2008) Correction of anemia with erythropoietin in chronic kidney disease (stage 3 or 4): effects on cardiac performance. Cardiovasc Drugs Ther 22: 37-44.
31. Kuriyama S, Tomonari H, Yoshida H, Hashimoto T, Kawaquchi Y, et al. (1997) Reversal of anemia by erythropoietin therapy retards the progression of chronic renal failure, especially in nondiabetic patients. Nephron 77: 176-185.
32. Revicki DA, Brown RE, Feeny DH, Henry D, Teehan BP, et al. (1995) Health-related quality of life associated with recombinant human erythropoietin therapy for predialysis chronic renal disease patients. Am J Kidney Dis 25: 548-554.
33. Nissenson AR, Korbet S, Faber M, Burkart J, Gentile D, et al. (1995) Multicenter trial of erythropoietin in patients on peritoneal dialysis. J Am Soc Nephrol 5: 1517-1529.
34. Sikole A, Polenakovic M, Spirovska V, Polenakovic B, Masin G, (1993) Analysis of heart morphology and function following erythropoietin treatment of anemic dialysis patients. Artif Organs 17: 977-984.
35. Teehan BP, Benz RL, Sigler MH, Brown JM, (1990) Early intervention with recombinant human erythropoietin therapy. Semin Nephrol 10: 28-34.
36. Strippoli GF, Craig JC, Manno C, Schena FP, (2004) Hemoglobin targets for the anemia of chronic kidney disease: a meta-analysis of randomized, controlled trials. J Am Soc Nephrol 15: 3154-3165.
37. Phrommintikul A, Haas SJ, Elsik M, Krum H, (2007) Mortality and target haemoglobin concentrations in anaemic patients with chronic kidney disease treated with erythropoietin: a meta-analysis. Lancet 369: 381-8.
38. Palmer SC, Navaneethan SD, Craig JC, Johnson DW, Tonelli M, et al. (2010) Meta-analysis: erythropoiesis-stimulating agents in patients with chronic kidney disease. Ann Intern Med 153: 23-33.
39. Obrador GT, Roberts T, St Peter WL, Frazier E, Pereira BJ, et al. (2010) Trends in anemia at initiation of dialysis in the United States. Kidney Int 60: 1875-84.
40. McMahon LP, Mason K, Skinner SL, Burge CM, Grigg LE, et al. (2000) Effects of haemoglobin normalization on quality of life and cardiovascular parameters in end-stage renal failure. Nephrol Dial Transplant 15: 1425-30.
41. FDA Drug Safety Communication (2011) Modified Dosing Recommendations to Improve the Safe Use of Erythropoiesis Stimulating Agents in Chronic Kidney Disease.